ANTX AN2 THERAPEUTICS INC Business Restructuring 8-K Filing 2024 - Workforce Reduction and Study Discontinuation AN2 Therapeutics, Inc. plans to reduce its workforce by 50% and discontinue its EBO-301 study, incurring charges of $2-$3 million.Get access to all SEC 8-K filings of the AN2 THERAPEUTICS INC